Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03075878 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)
A Phase 1 study, sponsored by Alexion Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT03075878 is a Phase 1 study that was terminated before completion, run by Alexion Pharmaceuticals. The registered enrollment target is 8 participants.
The verdict
NCT03075878, a Phase 1 study, was terminated before completion, sponsored by Alexion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This main study objective was to evaluate the safety and tolerability of intravenous (IV) SYNT001 (ALXN1830) in participants with WAIHA.
Interventions
- DRUG ALXN1830
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-01-10 |
| Est. Completion | 2019-08-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03075878
The ClinicalTrials.gov registry entry for NCT03075878 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ALXN1830 is the first listed.
NCT03075878 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03075878 about?
NCT03075878 is a clinical study titled "A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)". This main study objective was to evaluate the safety and tolerability of intravenous (IV) SYNT001 (ALXN1830) in participants with WAIHA.
What is the current status of trial NCT03075878?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2018-01-10. Estimated completion is 2019-08-06.
What interventions are being tested in trial NCT03075878?
The interventions under investigation include: ALXN1830 (DRUG).
Who is sponsoring clinical trial NCT03075878?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.